Clinical trial NCT06331156: A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants
Official title: A Phase III, Open-label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Porcine Circovirus (PCV)-Free Liquid Formulation of an Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Chinese Infants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Gastroenteritis
Keywords: Human rotavirus (HRV)
Rotarix Porcine circovirus (PCV)-free liquid
Inactivated poliovirus vaccine (IPV)
Healthy Chinese infants
Immunogenicity
Safety
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2024-03-26
Enrollment: 400
Sex: ALL
Minimum age (years): 6
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the immune response and safety of the inactivated poliovirus (IPV) vaccine when co-administered with the human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in healthy Chinese infants 6-10 weeks of age at the time of study enrolment.


Eligibility criteria: Inclusion Criteria:

* Participants' parent(s)/Legally Acceptable Representative(s) \[LAR(s)\], who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
* Healthy participants as established by medical history and clinical examination before entering into the study.
* A male or female of Chinese origin, between and including, 6 and 10 weeks (42-76 days) of age at the time of study enrolment.
* Born after a gestation period of 36 to 42 weeks inclusive.

Exclusion Criteria:

Medical conditions

* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
* Hypersensitivity to latex.
* History of severe combined immunodeficiency.
* History of seizures or progressive neurological disease.
* Family history of congenital or hereditary immunodeficiency.
* Uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception (IS).
* History of IS.
* Major congenital defects, or serious chronic illness as assessed by the investigator.
* Any contraindications to IPV.
* Previous confirmed occurrence of rotavirus gastroenteritis (RVGE).
* History of poliomyelitis.
* Participants with confirmed or suspected Coronavirus Disease 2019 (COVID-19).

Prior/Concomitant therapy

* Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the first dose of study interventions (Day -29 to Day 1), or planned use during the study period.
* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study interventions administration\*, with the exception of the inactivated influenza vaccine, which is allowed at any time during the study and other licensed routine childhood vaccinations.

  \*In case emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.
* Administration of long-acting immune-modifying drugs from birth or planned administration at any time during the study period.
* Administration of immunoglobulins and/or any blood products or plasma derivatives from birth or planned administration during the study period.
* Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone \>=0.5 milligram/kilogram (kg)/day, or equivalent. Inhaled, intra-articular and topical steroids are allowed.
* Previous vaccination against RV.
* Previous vaccination against poliomyelitis.

Prior/Concurrent clinical study experience

- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention.

Other exclusions

- Child in care.

Primary outcomes:
measure: Percentage of participants with seroconversion for anti-poliovirus types 1, 2 and 3 neutralizing antibody (Ab)
timeFrame: At 1 month post-Dose 3 of IPV (Month 3.5)
Secondary outcomes:
measure: Anti-poliovirus types 1, 2 and 3 neutralizing Ab geometric mean titers (GMTs)
timeFrame: At 1 month post-Dose 3 of IPV (Month 3.5)
measure: Percentage of participants with anti-poliovirus types 1, 2 and 3 neutralizing Ab titers >=1:8 and >=1:64
timeFrame: At 1 month post-Dose 3 of IPV (Month 3.5)
measure: Percentage of participants with seroconversion for anti-rotavirus (RV) immunoglobulin A (IgA) Ab
timeFrame: At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
measure: Anti-RV IgA Ab geometric mean concentrations (GMCs)
timeFrame: At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
measure: Percentage of participants with anti-RV IgA Ab concentrations >= 90 U/mL
timeFrame: At 1 month post-Dose 2 of HRV PCV-free (Month 2 for Staggered Group and Month 2.5 for Co-administration Group)
measure: Percentage of participants reporting solicited systemic events
timeFrame: Within 14 days after Dose 1 and Dose 2 of HRV PCV-free and IPV (Dose 1&2 administered at Day 1 & Month 1 (HRV PCV-free) and at Month 0.5 & Month 1.5 (IPV) for Staggered Group and at Month 0.5 & Month 1.5 (HRV PCV-free & IPV) for Co-administration Group)
measure: Percentage of participants reporting unsolicited adverse events (AEs)
timeFrame: Within 31 days after each dose of HRV PCV-free (HRV PCV-free administered at Day 1 and Month 1 for Staggered Group and at Month 0.5 and Month 1.5 for Co-administration group)
measure: Percentage of participants reporting serious adverse events (SAEs)
timeFrame: From the first dose of the study intervention (Day 1 for Staggered group and Month 0.5 for Co-administration group) up to study end (Month 3.5)
Other outcomes:
Locations:
city: Mianyang
country: China
facility: GSK Investigational Site
city: Neijiang
country: China
facility: GSK Investigational Site
city: Wenshan
country: China
facility: GSK Investigational Site
city: Wenshan
country: China
facility: GSK Investigational Site
city: Yuechi-Guang'an
country: China
facility: GSK Investigational Site
Study officials:
References: